SEC INSIDER TRANSACTIONS

BECTON DICKINSON & CO (BDX) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

BDX · BECTON DICKINSON & CO

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 22 filings · fetched 2026-11-13T16:39:22Z

Recent reported activity

0purchase rows on this page

2sale rows on this page

30matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-06-01Filed 2026-06-03	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $145.21 through $147.49. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. F2 Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. F3 Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F4 The stock appreciation rights vested in four annual installments beginning November 26, 2017. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	2,764D	146.35	Direct	Form 4 ↗0001628280-26-040095
2026-06-01Filed 2026-06-03	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $145.21 through $147.49. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. F2 Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. F3 Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F4 The stock appreciation rights vested in four annual installments beginning November 26, 2017. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	D Other reported codeCommon Stock · Non-derivative	17,445D	146.15	Direct	Form 4 ↗0001628280-26-040095
2026-06-01Filed 2026-06-03	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $145.21 through $147.49. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. F2 Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. F3 Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F4 The stock appreciation rights vested in four annual installments beginning November 26, 2017. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	M Exercise / conversionCommon Stock · Non-derivative	20,209A	126.16	Direct	Form 4 ↗0001628280-26-040095
2026-06-01Filed 2026-06-02	Menziuso PeterOfficer · EVP and President, BDI Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. References: F1	A Award / grantCommon Stock · Non-derivative	14,258A	0	Direct	Form 4 ↗0001628280-26-039738
2026-05-26Filed 2026-05-27	Feld MichaelOfficer · EVP, Chief Revenue Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 7, 2025. References:	S Sale (market/private)Common Stock · Non-derivative	75D	147.35	Direct	Form 4 ↗0001628280-26-038382

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.